Immune thrombocytopenic purpura caused by combination therapy of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A case presentation-Reference-Cited by-同舟云学术

Immune thrombocytopenic purpura caused by combination therapy of atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A case presentation

Published:2022-07-01 Issue:7 Volume:63 Page:335-341
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Kuwano Akifumi¹,Tanaka Kosuke¹,Nagasawa Shigehiro¹,Morita Yusuke¹,Yada Masayoshi¹,Masumoto Akihide¹,Motomura Kenta¹

Affiliation:

1. Department of Hepatology, Aso Iizuka Hospital

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/63/7/63_335/_pdf

Reference21 articles.

1. 1) Calvo R. Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia. Front Pharmacol 2019; 10: 454

2. 2) Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 2019; 6: e48-e57

3. 3) Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894-1905

4. 4) Xie W, Hu N, Cao L. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review. Front Immunol 2021; 9 (12): 790051

5. 5) Liu X, Liang X, Liang J, et al. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review. Front Oncol 2020; 7 (10): 530478

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2022-09-17